About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Ohio | 20,938 Studies Near You | Clareo Health

Clinical Trials LocationsOhio

Clinical Trials in Ohio

Discover 20,938 clinical trials near Ohio. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 13581-13600 of 20,938 trials

COMPLETEDPhase 232 miles

Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy

NCT02112838

The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of IgA Nephropathy

IGA Nephropathy

Rigel Pharmaceuticals76 participantsStarted Oct 2014

Palo Alto, California, United States • Augusta, Georgia, United States • Columbus, Ohio, United States +17 more locations

COMPLETED32 miles

Tylenol Levels in Bariatric Patients

NCT02982928

The current study is designed to measure and evaluate the pharmacokinetic profiling of acetaminophen in the young obese patient population.

Nationwide Children's Hospital11 participantsStarted Mar 2017

Columbus, Ohio, United States

Find Trials by Condition in Ohio

Breast Cancerin Ohio Lung Cancerin Ohio Prostate Cancerin Ohio Colorectal Cancerin Ohio Melanomain Ohio Leukemiain Ohio Lymphomain Ohio Pancreatic Cancerin Ohio Ovarian Cancerin Ohio Brain Cancerin Ohio Diabetesin Ohio

Data from ClinicalTrials.govTerms

TERMINATEDPhase 278 miles

Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide

NCT02379390

Primary Objective: To demonstrate the superiority in term of radiographic Progression-Free Survival (rPFS) of cabazitaxel at at 25 milligram per meter square (mg/m\^2) plus prednisone (Arm A) versus either enzalutamide at 160 milligram (mg) once daily or abiraterone acetate at 1000 mg once daily plus prednisone (Arm B) in chemotherapy-naïve participants with metastatic Castration-Resistant Prostate Cancer (mCRPC) who have disease progression while receiving androgen receptor (AR) targeted therapy (abiraterone plus prednisone or enzalutamide) within 12 months of treatment initiation (≤12 months). Secondary Objective: * To compare efficacy for: * Prostate-specific antigen (PSA) response rate and Time to PSA progression (TTPP). * Progression Free Survival (PFS). * Overall Survival (OS). * Tumor response rate in participants with measurable disease (RECIST 1.1) * Pain response and time to pain progression. * Symptomatic skeletal events (SSE) rate and time to occurrence of any SSE. * To analyze messenger ribonucleic acids (mRNAs) including androgen-receptor splice variant 7 messenger RNA (AR-V7) as a biomarker in Circulating Tumor Cells (CTCs). * To evaluate safety in the 2 treatment arms.

Prostate Cancer Metastatic

Sanofi8 participantsStarted Jun 2015

Muscle Shoals, Alabama, United States • Anchorage, Alaska, United States • Anaheim, California, United States +21 more locations

COMPLETEDPhase 287 miles

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)

NCT02559570

The purpose of this study was to evaluate dose response of the safety and efficacy of linaclotide for the treatment of functional constipation (FC), in children age 6-17 years. This study includes up to a 4-week Screening Period, and a 2 to 3-week Pretreatment Period. Participants age 6-11 years will receive oral liquid formulation and participants 12-17 years will receive solid oral capsule or liquid oral solution. Children ages 6-11 years meeting the entry criteria will be randomized to 1 of 3 doses of linaclotide or placebo for 4 weeks. Children ages 12-17 years meeting the entry criteria will be randomized to 1 of 4 doses of linaclotide or placebo for 4 weeks. This 4-week study will assess the effects of linaclotide on bowel movement frequency, as well as other bowel symptoms of FC.

Functional Constipation in Children Ages 6-17 Years

Forest Laboratories173 participantsStarted Nov 2015

Hot Springs, Arkansas, United States • Little Rock, Arkansas, United States • Anaheim, California, United States +59 more locations

COMPLETED95 miles

Understanding Quality and Equity in Wheelchairs for Veterans

NCT01236170

The Department of Veterans Affairs (VA) provides wheelchairs to about 42,000 Veterans with SCI and more than 40,000 Veterans with amputated limbs (AL). Despite VA's efforts to remove financial and other barriers to the provision of wheelchairs to all Veterans who need them, preliminary evidence suggests that disparities exist in the quality of wheelchairs prescribed to racial minorities and low income Veterans with SCI or AL. The proposed project will provide important information to the VA about the quality and equity of wheelchairs provided to Veterans with SCI or AL, and it will identify the patient and provider factors associated with wheelchair provision. Because Veterans with SCI and AL are considered special disability populations, identifying and understanding these factors is a critical first step to developing interventions to increase the quality and equity of wheelchairs provided to all disabled Veterans.

Spinal Cord InjuriesAmputees

VA Office of Research and Development497 participantsStarted Mar 2011

Tampa, Florida, United States • The Bronx, New York, United States • Cleveland, Ohio, United States +2 more locations

COMPLETEDPhase 295 miles

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years

NCT00802464

The goal of this randomized observer-blind trial is to further refine the formulation of vaccines containing GSK1437173A in older adults by comparing the cellular and humoral immune responses and the safety profiles of the different formulations.

GlaxoSmithKline410 participantsStarted Jan 2009

Phoenix, Arizona, United States • Pembroke Pines, Florida, United States • Las Vegas, Nevada, United States +9 more locations

COMPLETEDPhase 495 miles

RNS® System LTT Study

NCT00572195

The RNS® System LTT study is designed to assess the ongoing safety and to evaluate the long-term efficacy of the RNS® System as an adjunctive therapy in reducing the frequency of seizures in individuals 18 years of age or older with partial onset seizures that are refractory to two or more antiepileptic medications. Candidates will continue to receive their epilepsy medications while participating in the trial.

NeuroPace230 participantsStarted Apr 2006

Phoenix, Arizona, United States • Los Angeles, California, United States • San Francisco, California, United States +30 more locations

TERMINATEDPhase 395 miles

A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT02247479

This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study evaluating the efficacy and safety of lampalizumab administered by intravitreal injections in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Geographic Atrophy

Hoffmann-La Roche906 participantsStarted Sep 2014

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Tucson, Arizona, United States +142 more locations

COMPLETED95 miles

Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease

NCT02492672

The current registry is being undertaken to assess the long-term (12 month) safety and tolerability of Venofer in the pediatric population with chronic kidney disease that requires intravenous iron maintenance therapy.

Chronic Kidney Disease

American Regent, Inc.50 participantsStarted Sep 2014

Palo Alto, California, United States • Jacksonville, Florida, United States • Miami, Florida, United States +6 more locations

COMPLETEDPhase 395 miles

Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

NCT01190189

This extension study is designed to assess the safety of GSK Biological's human papillomavirus (HPV) vaccine GSK580299 in female subjects who took part in the primary study NCT00294047 and received the control vaccine in countries for which the licensed GSK HPV vaccine is not indicated for the subject's age group (26 years and older). This study is thus conducted to enable all women who received the control placebo in the primary NCT00294047 study to receive the GSK580299 vaccine.

Infections, Papillomavirus

GlaxoSmithKline137 participantsStarted Apr 2011

Aurora, Colorado, United States • Golden, Colorado, United States • Coral Gables, Florida, United States +25 more locations

TERMINATEDNA95 miles

A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache

NCT02991430

This study will assess the efficacy of a neuromodulation device for the treatment of episodic migraine headache.

Scion NeuroStim45 participantsStarted Jun 2017

Scottsdale, Arizona, United States • West Palm Beach, Florida, United States • Chicago, Illinois, United States +7 more locations

COMPLETEDPhase 1/2135 miles

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas

NCT02401048

The purpose of this study is to evaluate the efficacy, safety and tolerability of the combination treatment of ibrutinib and MEDI4736 in subjects with relapsed or refractory lymphomas.

Diffuse Large B-Cell LymphomaFollicular Lymphoma

Pharmacyclics LLC.61 participantsStarted May 2015

Birmingham, Alabama, United States • Duarte, California, United States • Stanford, California, United States +8 more locations

COMPLETEDPhase 3141 miles

Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis

NCT03824912

Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis

Encube Ethicals Pvt. Ltd.831 participantsStarted Aug 2018

Long Beach, California, United States • Miami, Florida, United States • Miami, Florida, United States +6 more locations

COMPLETEDPhase 1/2146 miles

Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously

NCT01543672

Treatment of larger tumor volumes or ≥ 2 lung metastases simultaneously in lung cancer patient using Stereotactic Body Radiation Therapy (SBRT) in a mean-lung dose escalation study.

Lung CancerMetastatic Lung Cancer

The Netherlands Cancer Institute62 participantsStarted Nov 2011

Royal Oak, Michigan, United States • Philadelphia, Pennsylvania, United States • Toronto, Ontario, Canada +2 more locations

COMPLETEDPhase 4181 miles

A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects

NCT02198651

The primary objective of the study was to investigate the association between residual disease activity at Baseline as detected by Magnetic Resonance Imaging (MRI) and the occurrence of flares in participants with rheumatoid arthritis (RA) randomized to an adalimumab dose tapering regimen controlled by adalimumab withdrawal.

Rheumatoid ArthritisMusculoskeletal and Connective Tissue Diseases

AbbVie149 participantsStarted Jan 2015

Tuscaloosa, Alabama, United States • Thousand Oaks, California, United States • Jacksonville, Florida, United States +67 more locations

COMPLETEDNA266 miles

Safety and Effectiveness of B-Laser™ in Subjects Affected With Infrainguinal PAD

NCT03157531

This is a prospective, single-arm, multi-center, international, open-label, clinical study.

Eximo Medical Ltd.97 participantsStarted Sep 2017

Little Rock, Arkansas, United States • Altamonte Springs, Florida, United States • Bradenton, Florida, United States +8 more locations

COMPLETED311 miles

National Prevalence and Impact of Noninvasive Prenatal Testing

NCT02284399

Information on pregnant women undergoing non-invasive prenatal testing (NIPT) at one of the Obstetrix Medical Groups Outpatient Centers between January 2012 and June 2014 will be retrospectively gathered and an analysis of the impact and prevalence of NIPT. This will be compared to a control group of pregnant women in those same practices undergoing prenatal testing during the months of January 2010-July 2010.

Obstetrix Medical Group4,488 participantsStarted Jan 2014

Phoenix, Arizona, United States • Long Beach, California, United States • San Jose, California, United States +4 more locations

COMPLETEDPhase 1364 miles

Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas

NCT01898078

The purpose of this study is to evaluate the effect of food on the single-dose pharmacokinetics (PK) of alisertib administered as an enteric-coated tablet (ECT) formulation in participants with advanced solid tumors or lymphomas.

Advanced Solid TumorsLymphoma

Millennium Pharmaceuticals, Inc.26 participantsStarted Jul 2013

The Bronx, New York, United States • Nashville, Tennessee, United States • San Antonio, Texas, United States

COMPLETEDPhase 2427 miles

A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene

NCT02651688

The purpose of this study is to compare the effects of 12 months of treatment with enclomiphene 12.5 mg, 25 mg, or placebo capsules on body composition and metabolic parameters in overweight men with acquired hypogonadotropic hypogonadism \[confirmed morning testosterone (T) ≤300 ng/dL\] following a 6 month diet and 15 month exercise program.

Acquired Hypogonadotropic HypogonadismObesity

Repros Therapeutics Inc.50 participantsStarted Jan 2016

Albany, New York, United States • Garden City, New York, United States • Providence, Rhode Island, United States +2 more locations

COMPLETEDPhase 1872 miles

A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta

NCT02019602

The primary purpose is to assess whether there is transfer of Certolizumab Pegol (CZP) from pregnant women receiving treatment with Cimzia® across the placenta to infants by evaluating the concentration of CZP in the plasma of infants at birth.

Axial Spondyloarthritis (AxSpA)Non-radiographic Evidence-AxSpAAnkylosing Spondylitis+3 more

UCB BIOSCIENCES, Inc.37 participantsStarted Jan 2014

Scottsdale, Arizona, United States • Oklahoma City, Oklahoma, United States • Salt Lake City, Utah, United States +5 more locations

PreviousPage 680 of 1047Next

Heart Diseasein Ohio